Teva Completes Enrollment for Schizophrenia Drug Trial: Phase 3 Results Anticipated in 2024
Teva Pharmaceutical Industries Ltd. has successfully completed patient enrollment for its Phase 3 trial of mdc-TJK, an innovative potential treatment for schizophrenia. The trial has enrolled 640 participants across the European Union and the United States, with results expected to be available in the latter half of 2024.
mdc-TJK: a Potential Novel Treatment for Schizophrenia, Combining Safety and Long-Acting Potential
Teva’s mdc-TJK (TEV-44749) is a once-monthly subcutaneous injection being developed as an atypical antipsychotic olanzapine formulation. It holds promise as a long-acting option with the potential to offer a favorable safety profile. This development is especially significant considering that the current long-acting injectable (LAI) olanzapine carries an FDA black box warning for Post-injection Delirium/Sedation Syndrome (PDSS), which has limited its use.
Teva and MedinCell Collaboration Aims to Improve Schizophrenia Treatment Options
Teva is taking the lead in the development and global commercialization of mdc-TJK, an olanzapine LAI. As part of this collaboration, MedinCell, a biopharmaceutical company specializing in long-acting injectable drugs, stands to receive up to $117 million in development and commercial milestones for mdc-TJK, along with royalties on net sales. This partnership underscores both companies’ commitment to advancing treatment options for schizophrenia, a chronic brain disorder that affects about 1% of the population worldwide.
MedinCell’s BEPO® Technology Shows Promise in FDA-Approved Treatment for Schizophrenia
MedinCell’s proprietary BEPO® technology, which controls drug delivery over extended periods, has already seen success with the FDA approval of UZEDY™ in April 2023. UZEDY™, a treatment for schizophrenia, is now available in the United States through Teva, under the licensed name SteadyTeq™. This FDA approval highlights the potential of MedinCell’s technology to enhance the efficacy and safety of long-acting injectable medications.
Advancing Therapeutic Effectiveness and Patient Compliance in Schizophrenia Treatment: Joint Efforts of Teva and MedinCell
The completion of patient enrollment for the mdc-TJK trial marks a significant milestone in the joint efforts of Teva and MedinCell to enhance therapeutic effectiveness and improve patient compliance in the treatment of schizophrenia. With the potential for a long-acting option that guarantees a favorable safety profile, mdc-TJK holds promise in meeting the unmet needs of patients with schizophrenia. This collaboration represents a step forward in the development of innovative treatment options for this chronic brain disorder.
Analyst comment
Positive news. Teva has completed patient enrollment for its Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia with a favorable safety profile. Results expected in 2024. Teva and MedinCell collaboration demonstrates commitment to improving schizophrenia treatment options. Market response: potential increase in Teva’s stock value.
